ArticleActa pharmacologica Sinica2026
Sino-C, a novel sinomenine derivative, induces cell death by disrupting cholesterol homeostasis in colorectal cancer cells.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, necessitating the discovery of novel therapeutic agents. Sinomenine (Sin), a natural product derived from traditional Chinese medicine, has been extensively modified to enhance its therapeutic potential. Here, we synthesized Sino-C, a novel Sin derivative, and evaluated its anti-CRC activity. Sino-C exhibited significant anticancer effects both in vitro and in vivo. Mechanistically, Sino-C upregulated cholesterol homeostasis-related genes and increased intracellular cholesterol levels in CRC cells. Cholesterol depletion with methyl-β-cyclodextrin (MβCD) alleviated Sino-C-induced cholesterol accumulation, reduced cell death, and reversed cleaved PARP expression, indicating cholesterol imbalance as a critical mediator of Sino-C's activity. Furthermore, Sino-C-induced cholesterol imbalance promoted lipid peroxidation and endoplasmic reticulum (ER) stress, contributing to cell death. The antioxidant vitamin E (Ve), N-acetylcysteine (NAC), or PERK inhibitor GSK2656157 could reverse these effects of Sino-C. Clinical correlation analysis further revealed that high expression of Sino-C-upregulated cholesterol homeostasis genes was linked to better survival outcomes in CRC cohorts. In conclusion, this study highlights the therapeutic potential of Sino-C in CRC. In vitro mechanistic findings suggest that Sino-C exerts its anticancer effects through modulation of cholesterol metabolism, positioning natural product derivatives as valuable candidates for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.